

Efficacy of metoprolol CR/XL on diabetic postoperative mortality and cardiovascular morbidity: a randomised, double blind, placebo-controlled, multicentre trial

Submission date
27/02/2002

Recruitment status
No longer recruiting

Prospectively registered

Protocol

Registration date
27/02/2002

Overall study status
Completed

Statistical analysis plan

Results

Last Edited
06/09/2007

Condition category
Nutritional, Metabolic, Endocrine

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Anne Benedicte Juul

Contact details

Copenhagen Trial Unit
Centre for Clinical Intervention Research
H:S Rigshospitalet
Dept 7102
Copenhagen Ø
Denmark
DK-2100
+45 3545 7156 or +45 3526 7235
Anne.j@ctu.rh.dk

Additional identifiers

Study information

Scientific Title

Acronym

DIPOM

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Diabetes mellitus and major surgery

Interventions

Diabetic patients undergoing major noncardiac surgery are randomised to 7 days of perioperative beta blocking (Metoprolol CR/XL [SeloZok®] 100 mg daily) versus placebo treatment.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Metoprolol CR/XL

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/07/2002

Eligibility

Key inclusion criteria

Patients 40 years of age with diabetes undergoing noncardiac major (lasting more than 1 hour) surgery

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex**Key exclusion criteria**

Not provided at time of registration

Date of first enrolment

01/07/2000

Date of final enrolment

01/07/2002

Locations**Countries of recruitment**

Denmark

Study participating centre**Copenhagen Trial Unit**

Copenhagen Ø

Denmark

DK-2100

Sponsor information**Organisation**

Copenhagen Trial Unit (Denmark)

ROR

<https://ror.org/05bpbnx46>

Funder(s)

Funder type

Charity

Funder Name

The Danish Heart Foundation (Denmark) (ref: 01-2-5-51A-22931)

Funder Name

The Danish Diabetes Foundation (Denmark) (ref: C.1)

Funder Name

The Copenhagen Hospital Corporation's Research Council (Denmark) (ref: 109/01)

Funder Name

Programme for Strengthening Regional Collaboration within Medical Health Research (Denmark) (ref: 301-070-5199)

Funder Name

AstraZeneca (Denmark) (ref: AD-MET-0003)

Alternative Name(s)

AstraZeneca PLC, Pearl Therapeutics, AZ

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	24/06/2006		Yes	No